Product Description
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Steba Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Esophagitis, Peptic
Phase 1: Duodenal Ulcer|Esophagitis|Stomach Ulcer|Gastroesophageal Reflux
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HPD/STU(-Na) 05819N/TU 1.41 | P1 |
Completed |
Stomach Ulcer|Gastroesophageal Reflux|Duodenal Ulcer|Esophagitis |
2006-11-01 |
|
HEC/STU(-Na)05816N/TU 2.05 | P2 |
Suspended |
Esophagitis, Peptic |
None |